In the Claims

1-15 (Canceled).

16. (New): A pharmaceutical composition comprising a pharmaceutically acceptable carrier and:

a) two or more antisense oligonucleotides complementary to a thymidylate synthase mRNA or analogues of said oligonucleotides;

b) two or more antisense oligonucleotides complementary to different regions of a thymidylate synthase mRNA or analogues of said oligonucleotides;

c) two or more antisense oligonucleotides or analogues thereof, wherein at least one of said antisense oligonucleotides or analogues thereof comprises at least 5 consecutive nucleotides selected from the nucleic acid sequences as set in forth in any one of SEQ ID NOs: 1, 2, 3, 5, 6 or 11;

d) two or more antisense oligonucleotides or analogues thereof, wherein said antisense oligonucleotides or analogues thereof comprises at least 5 consecutive nucleotides selected from the nucleic acid sequences as set in forth in any one of SEQ ID NOs: 1, 2, 3, 5, 6 or 11;

e) two or more antisense oligonucleotides or analogues of said oligonucleotides, wherein the sequences of two oligonucleotides of the combination are selected from SEQ ID NO: 1 and 2 or SEQ ID NO: 1 and 3;

f) oligonucleotide analogues according to a), b), c), d) or e), wherein said analogues comprise one or more phosphorothioate linkages; or

g) oligonucleotide analogues according to a), b), c), d), e) or f), wherein said analogues comprise one or more 2'-methoxy-ethoxy substituted nucleotide.

17. (New): The pharmaceutical composition according to claim 16, further comprising one or more chemotherapeutic agent.

18. (New): A method of treating cancer comprising the administration of a pharmaceutical composition according to claim 16 to an individual.

19. (New): The method according to claim 18, wherein said composition comprises two or more antisense oligonucleotides complementary to a thymidylate synthase mRNA or analogues of said oligonucleotides.

20. (New): The method according to claim 18, further comprising the administration of one or more chemotherapeutic agent for the treatment of cancer.

21. (New): The method according to claim 18, wherein said composition comprises two or more antisense oligonucleotides or analogues of said oligonucleotides and the sequences of two oligonucleotides of the combination are selected from SEQ ID NO: 1 and 2 or SEQ ID NO: 1 and 3.

22. (New): The method according to claim 21, further comprising the administration of one or more chemotherapeutic agent for the treatment of cancer.

23. (New): The method according to claim 18, wherein the administration of said composition enhances the anti-tumor effect of standard doses of the one or more chemotherapeutic agents.

24. (New): The method according to claim 20, wherein the administration of said composition and one or more chemotherapeutic agent reduces the amount of chemotherapeutic required to effectively treat an individual with cancer.

25. (New): The method according to claim 20, wherein the administration of said composition and one or more chemotherapeutic agent enhances the anti-tumor effect of standard doses of the one or more chemotherapeutic agents.

26. (New): The method according to claim 22, wherein the administration of said composition reduces the amount of chemotherapeutic required to effectively treat an individual with cancer.

27. (New): The method according to claim 22, wherein the administration of said composition enhances the anti-tumor effect of standard doses of the one or more chemotherapeutic agents.

28. (New): The method according to claim 18, wherein said composition reduces the number of neoplastic cells in said mammal.

29. (New): The method according to claim 20, wherein said composition reduces the number of neoplastic cells in said mammal.

30. (New): A method of sensitizing neoplastic cells to a chemotherapeutic agent comprising contacting said neoplastic cells with a composition according to claim 16.